Background and Purpose
The purpose of this study is to evaluate dose escalation of BG34-200 in dogs with cancer. We will 1) evaluate the safety of BG34-200, and 2) evaluate the ability of BG34-200 to stimulate a patient’s immune system to detect and destroy cancer cells.
Study Location
Participation Criteria
There will be about 6-10 dogs taking part in this study at Tufts University.
- Dogs weighing more than 15kg (33 lbs) who have been diagnosed with a solid tumor.
- Both newly diagnosed and those with recurrent/relapsed disease are eligible.
- Dogs with lymphoma, mast cell tumors, or hemangiosarcoma are not eligible.
Study Details
- Before your pet begins the study, your pet will need to have the following tests and/or procedures to find out if he/she can be in the study: bloodwork, urinalysis, chest x-rays, and abdominal ultrasound. If a diagnosis has not been made, additional diagnostic tests such as a fine needle aspirate may be required to determine a diagnosis.
- If the exams, tests, and procedures show that your pet can take part in the study, and you choose to enroll them, then the following will happen as part of the study:
- Your dog will come in weekly for 5 weeks.
- Weeks 1 and 5 will require a tumor biopsy.
- Your dog will receive 4 weekly intravenous infusions of BG34-200.
- Blood samples will be collected at each study visit.
- Consent for a necropsy (autopsy, if your pet dies) is required to be eligible for this study.
Contact Information
Please contact the study site if you’re interested in seeing if your dog is eligible to participate.
- Tufts University: Email the clinical trials office at clinicaltrials@tufts.edu